We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.
We believe that our lead product candidates have demonstrated, in clinical trials and/or in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.
 |
|
|
|
|
| RELOVAIR™ (LABA/ICS): COPD |
REGULATORY SUBMISSION PLANNED |
|
| RELOVAIR™ (LABA/ICS): Asthma |
REGULATORY SUBMISSION PLANNED |
|
| GSK573719/Vilanterol (LAMA/LABA): COPD |
|
|
|
|
|
| |
| TD-1792 (GP-Ceph Heterodimer): Serious Gram+ Infections |
|
| |
| TD-1211 (PµMA): Opioid - Induced Constipation |
|
|
|
| |
| TD-5108 (velusetrag, 5-HT4 agonist): GI Motility Dysfunction |
|
| TD-8954 (5-HT4 agonist): GI Motility Dysfunction |
|
| |
| TD-5108 (5-HT4 agonist): Alzheimer's Disease |
|
Key:
- ADHD: Attention Deficit Hyperactivity Disorder
- CNS: Central Nervous System
- GI: Gastrointestinal
- GP-Ceph: Glycopeptide-Cephalosporin
- ICS: Inhaled Corticosteroid
- LABA: Long-Acting Beta2 Agonist
- LAMA: Long-Acting Muscarinic Antagonist
- MABA: Bifunctional Muscarinic Antagonist-Beta2 Agonist
- MARIN: Monoamine Reuptake Inhibitor
- PµMA: Peripheral Mu Opioid Receptor Antagonist
In the table above:
- Development Status indicates the most advanced stage of development that has been completed or is in process.
- Phase 1 indicates initial clinical safety testing in healthy volunteers, or studies directed toward understanding the mechanisms of action of the drug.
- Phase 2 indicates further clinical safety testing and preliminary efficacy testing in a limited patient population.
- Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
- Filed indicates that a New Drug Application or European Marketing Authorization Application has been submitted to and accepted for filing by the U.S. Food and Drug Administration or European Medicines Agency, respectively.
We consider programs in which at least one compound has successfully completed a Phase 2a study showing efficacy and tolerability as having achieved Proof-of-Concept.
